# Palvella Therapeutics Inc. (PVLA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $157.24, market value $2.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Palvella Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 52.9×**. Each dollar of revenue is priced at 52.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 10.4×**. The shares trade at 10.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -27.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: -149.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: 31.4%**. Each dollar of assets produces 31.4% of profit.

## Growth
- **EPS growth (1 yr): 52.6%**. Earnings per share rose 52.6%.

## Financial health
- **Current ratio: 5.20** (quick 5.20). Current assets cover the next year's liabilities 5.20 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Palvella Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover Palvella Therapeutics Inc.; the consensus is strong_buy, with an average price target of $230.53 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 190.4%** (YTD 50.2%, 3-mo 44.7%). The shares are up 190.4% over twelve months including dividends.
- **From 52-week high: -2.6%** (195.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.76** (volatility 84%). Beta of 1.76 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PVLA · Page: https://foliofundamentals.com/stocks/pvla

Not investment advice.